iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader
providing innovative cancer detection and therapy solutions, today
announced compelling new long-term real-world research
confirms Xoft Skin eBx is as safe and effective as Mohs
surgery for the treatment of non-melanoma skin cancer (NMSC). In
the longest-term study of Xoft Skin eBx to-date, published in the
Journal of Contemporary Brachytherapy, 98.9% of patients remained
recurrence-free at a median follow-up of 7.6 years.
“NMSC is the most commonly diagnosed cancer in the U.S. and its
incidence continues to grow worldwide.1,2 With a disease this
prevalent, clinicians need proven solutions and treatment plans as
individualized as each patient,” said Dana Brown, President and CEO
of iCAD, Inc. “Xoft Skin eBx is changing the face of non-melanoma
skin cancer treatment. This study adds to the body of clinical
evidence that puts Xoft Skin eBx on par with Mohs surgery with
regards to safety, efficacy, and recurrence rates, but with fewer
side effects and more comfort and convenience for patients. Xoft
offers the potential to positively impact the lives of cancer
patients and the providers who care for them on a global scale, and
we are pleased to see the body of evidence supporting this
technology continue to grow with the publication of this
study.”
Xoft Skin eBx offers a painless, noninvasive NMSC treatment
approach that precisely targets cancer cells, while sparing healthy
tissue. Using a small surface applicator placed on the skin, Xoft
Skin eBx targets cancer directly over a short series of office
visits lasting a few minutes each. The high dose, low energy
treatment allows medical personnel to remain in the room and
enables patients to return to normal daily activities immediately,
with no downtime – maximizing outcomes and minimizing side effects
for patients.
The long-term real-world study evaluated 180 patients with 182
NMSC lesions treated with Xoft Skin eBx at four study centers in
Northern and Southern California. With a recurrence rate of 1.1% at
a mean follow up of 7.5 years, researchers concluded Xoft Skin eBx
is safe and effective, showing excellent long-term local control
and minimal long-term toxicities.
“Because non-melanoma skin cancer is typically caused by sun
exposure, it inherently strikes in some of the most visible places
on the body, such as the face, scalp, nose, ears, arms, and legs.
Unfortunately, these areas can also be some of the toughest places
to remove lesions surgically. And for some patients, surgery is not
an option or a preference,” said Stephen Doggett, MD, FACR,
Radiation Oncologist, Aegis Oncology. “Our study confirms that Xoft
Skin eBx offers a safe and effective treatment option for NMSC that
is as effective as Mohs surgery, but with fewer side effects.”
Xoft Skin eBx is particularly ideal in treating anatomically
challenging locations, as well as areas prone to difficulties in
wound healing, making it a viable option for patients who are not
surgical candidates due to medical comorbidities or other health
issues. Other skin conditions such as keloids are also suitable for
treatment with skin eBx.
“Xoft Skin eBx arms clinicians with a safe and effective
alternative to surgery that can be seamlessly integrated in
virtually any clinical setting. This comprehensive, end-to-end
solution is supported by a full-service oncology program, offering
the flexibility and simplicity clinicians need and the comfort and
convenience patients deserve. Xoft offers a versatile tool in the
toolbox that is tough on tumors but gentle on patients, and we are
pleased to provide this clinically proven treatment to facilities
and patients worldwide,” added Ms. Brown.
About iCAD, Inc.Headquartered in Nashua, NH,
iCAD® is a global medical technology leader providing innovative
cancer detection and therapy solutions. For more information, visit
www.icadmed.com.
Forward-Looking StatementsCertain statements
contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements about the expansion of
access to the Company’s products, improvement of performance,
acceleration of adoption, expected benefits of ProFound AI®, the
benefits of the Company’s products, and future prospects for the
Company’s technology platforms and products. Such forward-looking
statements involve a number of known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance, or achievements of the Company to be materially
different from any future results, performance, or achievements
expressed or implied by such forward-looking statements. Such
factors include, but are not limited, to the Company’s ability to
achieve business and strategic objectives, the willingness of
patients to undergo mammography screening in light of risks of
potential exposure to Covid-19, whether mammography screening will
be treated as an essential procedure, whether ProFound AI will
improve reading efficiency, improve specificity and sensitivity,
reduce false positives and otherwise prove to be more beneficial
for patients and clinicians, the impact of supply and manufacturing
constraints or difficulties on our ability to fulfill our orders,
uncertainty of future sales levels, to defend itself in litigation
matters, protection of patents and other proprietary rights,
product market acceptance, possible technological obsolescence of
products, increased competition, government regulation, changes in
Medicare or other reimbursement policies, risks relating to our
existing and future debt obligations, competitive factors, the
effects of a decline in the economy or markets served by the
Company; and other risks detailed in the Company’s filings with the
Securities and Exchange Commission. The words “believe,”
“demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place
undue reliance on those forward-looking statements, which speak
only as of the date the statement was made. The Company is under no
obligation to provide any updates to any information contained in
this release. For additional disclosure regarding these and other
risks faced by iCAD, please see the disclosure contained in our
public filings with the Securities and Exchange Commission,
available on the Investors section of our website at
http://www.icadmed.com and on the SEC’s website at
http://www.sec.gov.
Contact:
Media Inquiries:Jessica Burns, iCAD
+1-201-423-4492jburns@icadmed.com
Investor Inquiries:iCAD Investor Relationsir@icadmed.com
1 Basic Information about Skin cancer. Centers for Disease
Control. https://www.cdc.gov/cancer/skin/basic_info/index.htm2
Radiation: Ultraviolet (UV) radiation and skin cancer. World Health
Organization.
https://www.who.int/news-room/questions-and-answers/item/radiation-ultraviolet-(uv)-radiation-and-skin-cancer
Icad (NASDAQ:ICAD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Icad (NASDAQ:ICAD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024